MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.acthis.2026.152349

Медицинская библиотека · Acta histochemica · 2026

YARS2 mediates PARPi resistance in pancreatic cancer by regulating the MYC-E2F axis.

Hu Yu, Yuan Peng, Bu Xiangyi, Jia Weidong, Cheng Yuan

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) resistance to PARP inhibitors (PARPi) remains poorly understood, the mechanism of resistance remain poorly understood.

MATERIAL AND

METHODS

We integrated multi-omics data from The Cancer Genome Atlas-Pancreatic Adenocarcinoma (TCGA-PAAD) datasets, Cancer Cell Line Encyclopedia (CCLE), and the Genomics of Drug Sensitivity in Cancer (GDSC) performed weighted gene co-expression network analysis (WGCNA) to identify hub genes linked to PARPi resistance. GSE86394 from the Gene Expression Omnibus (GEO) database was utilized to differential expressed genes (DEGs) and performed functional enrichment analyses. CCK8, flow cytometry, Transwell assay were conducted to detected cell viability, apoptosis, and migration. Xenograft models was conducted to investigate the effect of YARS2 on PARPi-resistant in vivo. Immunohistochemistry (IHC) was used to detect the expression of various proteins. Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) was utilized to assess cells apoptosis. Gene and protein expression were detected by quantitative reverse transcription PCR (qRT-PCR) and western blotting (WB), respectively.

RESULTS

YARS2 was identified as a PARPi resistance hub gene, whose high expression correlated with poor prognosis in PDAC. YARS2 was significantly upregulated in PARPi-resistant PDAC cells, and its knockdown reversed PARPi resistance in vitro and in vivo. Mechanistically, YARS2 knockdown suppressed the expression of the c-MYC, E2F1 and elevated levels of phosphorylated histone H2AX (γ-H2AX). However, the overexpression of c-MYC was reversed the inhibitory role of YARS2 knockdown in PARPi-resistant PDAC cells.

CONCLUSION

Our findings reveal that YARS2 mediates PARPi resistance via the MYC/E2F1 pathway in PDAC, highlighting YARS2 may serve as a potential target for therapy to counteract PARPi resistance.

Для цитирования: Hu Yu, Yuan Peng, Bu Xiangyi, Jia Weidong, Cheng Yuan. YARS2 mediates PARPi resistance in pancreatic cancer by regulating the MYC-E2F axis.. Acta histochemica. 2026. DOI: 10.1016/j.acthis.2026.152349.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.